NCT04279119已完成1 期
An Open Label, Phase 1, Maximal Usage Pharmacokinetics and Safety Study of ARQ-151 Cream 0.3% Administered QD in Adolescent and Adult Subjects With Chronic Plaque Psoriasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 26
- 试验地点
- 12
- 主要终点
- Maximum concentration (Cmax) of roflumilast and its major N-oxide metabolite
研究概览
简要总结
This is a phase 1, open label, single arm study in which ARQ-151 cream 0.3% is applied QD for 2 weeks to adolescent subjects with chronic plaque psoriasis involving at least 10% body surface area (BSA) and adult subjects with chronic plaque psoriasis involving at least 20% BSA (excluding scalp).
The objectives of this study are to evaluate the exposure and characterize the plasma pharmacokinetic profile and to assess the safety and tolerability of ARQ-151 cream 0.3% administered once daily for 2 weeks to adolescent and adult subjects with chronic plaque psoriasis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants legally competent to sign and give informed consent or for adolescents assent with consent of a parent or legal guardian.
- •Males and females ages 12 years and older (inclusive) at the time of consent/assent.
- •Clinical diagnosis of psoriasis vulgaris of at least 3 months duration as determined by the Investigator or through subject interview. Stable disease for the past 4 weeks.
- •Psoriasis vulgaris on the face, extremities, trunk, and/or intertriginous areas involving at least 10% of BSA in adolescents and at least 20% of BSA in adults (excluding the scalp).
- •An Investigator Global Assessment of disease severity of at least Moderate ('3') at Baseline.
- •Females of childbearing potential (FOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception throughout the trial.
- •Females of non-childbearing potential should be premenarchal, post-menopausal with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization.
- •Subjects in good health as judged by the Investigator, based on medical history, physical examination, vital signs, 12-lead electrocardiogram, serum chemistry labs, hematology values, and urinalysis.
- •Subjects are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.
排除标准
- •Subjects who cannot discontinue medication and treatments prior to the Baseline visit and during the study according to Excluded Medications and Treatments (Table 1).
- •Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other light emitting diode (LED).
- •Subjects currently taking lithium or antimalarial drugs.
- •Planned initiation or changes to concomitant medication that could, in the opinion of the Investigator, affect psoriasis vulgaris (e.g. beta blockers, ACE inhibitors).
- •Current diagnosis of non-plaque form of psoriasis (e.g., guttate, erythrodermic/exfoliative, or pustular psoriasis). Current diagnosis of drug-induced psoriasis.
- •Subjects with any condition on the treatment area which, in the opinion of the Investigator, could confound efficacy measurements.
- •Known allergies to excipients in ARQ-151 cream
- •Subjects who cannot discontinue the use of systemic strong P 450 cytochrome inhibitors (e.g., indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, fluconazole, nefazodone, saquinavir, suboxone and telithromycin) for two weeks prior to the Baseline visit and during the study period.
- •Subjects who cannot discontinue the use of systemic strong P 450 cytochrome inducers (e.g., efavirenz, nevirapine, glucocorticoids, barbiturates (including phenobarbital), phenytoin, rifampin and carbamazepine) for two weeks prior to the Baseline visit and during the study period.
- •Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
- •Subjects who have received oral roflumilast (Daliresp®, Daxas®) or other PDE4 inhibitors (apremilast) within the past 4 weeks.
- •Known or suspected:
- •severe renal insufficiency or moderate to severe liver impairment (Child-Pugh B or C)
- •known HIV infection
- •hypersensitivity to component(s) of the investigational products
- •history of severe depression, suicidal ideation, Baseline/Screening C-SSRS indicative of suicidal ideation, whether lifetime or recent/current
- •Adult subjects with PHQ-8 ≥10 or adolescent subjects with modified PHQ-A ≥10 at Screening or Baseline visits.
- •Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of investigational product.
- •Subjects with a history of a major surgery within 4 weeks prior to Baseline (Visit 2) or has a major surgery planned during the study.
- •Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation. For adolescent subjects; parent(s)/legal guardian(s) who are unable to communicate, read, or understand the local language.
- •Subjects who are family members of the clinical study site, clinical study staff, or Sponsor.
- •Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
- •Current or a history of cancer within 5 years with the exception of fully treated skin basal cell carcinoma, cutaneous squamous cell carcinoma or carcinoma in situ of the cervix.
- •Subjects with active infection that required oral or intravenous administration of antibiotics, antifungal or antiviral agents within 7 days of Baseline/Day 1.
研究组 & 干预措施
ARQ-151 cream 0.3%
Experimental
Open label study of ARQ-151 cream 0.3% applied once daily for 2 weeks
干预措施: ARQ-151- cream 0.3% (Drug)
结局指标
主要结局
Maximum concentration (Cmax) of roflumilast and its major N-oxide metabolite
时间窗: 5 weeks
Maximum observed concentration of drug in plasma metabolite
Area under the plasma concentration-time curve until the last quantifiable timepoint (AUC) for roflumilast and its N-oxide metabolite
时间窗: 5 weeks
The area under the plasma concentration-time curve (AUC) is a method of measurement of the total exposure of a drug in plasma.
Time of maximum concentration (Tmax) of roflumilast and its major N-oxide metabolite
时间窗: 5 weeks
Tmax is the time that a drug achieves maximum concentration in plasma
次要结局
- Subject incidence of adverse events(5 weeks)
- Incidence of application site reactions(5 weeks)
- The incidence of suicide ideation as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)(5 weeks)
- The incidence of changes from baseline in the Patient Health Questionnaire (PHQ-8) Depression Scale(5 weeks)
- The incidence of changes from baseline in the Patient Health Questionnaire for Adolescents (PHQ-A) Depression Scale(5 weeks)
研究者
研究点 (12)
Loading locations...
相似试验
已完成
2 期
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)PsoriasisPlaque PsoriasisNCT04655313Arcutis Biotherapeutics, Inc.20
已完成
2 期
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)Plaque PsoriasisPsoriasisNCT04746911Arcutis Biotherapeutics, Inc.10
已完成
3 期
Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic DermatitisAtopic Dermatitis EczemaNCT04804605Arcutis Biotherapeutics, Inc.1,220
已完成
3 期
Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisChronic Plaque PsoriasisNCT04286607Arcutis Biotherapeutics, Inc.337
已完成
3 期
Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisChronic Plaque PsoriasisNCT04211389Arcutis Biotherapeutics, Inc.442